Rituximab for rheumatoid arthritis.
Okamoto
Hiroshi
H
Kamatani
Naoyuki
N
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology*; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001323:Autoantibodies; D001402:B-Lymphocytes; D001424:Bacterial Infections / Q000209:etiology; D003141:Communicable Diseases / Q000209:etiology*; D006801:Humans; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D018501:Antirheumatic Agents; D001323:Autoantibodies; D000069283:Rituximab